摘要:
A bioinformatic method for identifying and isolating proteins and peptides with MSCRAMM®-like characteristics from Gram positive bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, and proteins and peptides obtained thereby are provided which can be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.
摘要翻译:提供了用于从革兰氏阳性细菌如肠球菌属,葡萄球菌属,链球菌属和芽孢杆菌属细菌鉴定和分离具有MSCRAMM®样特征的蛋白质和肽的生物信息学方法,以及由此得到的蛋白质和肽,其可用于预防和治疗 革兰氏阳性菌引起的感染。 该方法包括从序列信息中鉴定具有推定的C末端LPXTG(SEQ ID NO:1)细胞壁分选信号的蛋白质和具有LPXTG锚定的细胞壁蛋白质的MSCRAMM®蛋白质的其他结构相似性的蛋白质。 使用本发明鉴定和分离的MSCRAMM蛋白质及其免疫原性区域可用于革兰氏阳性细菌感染的诊断,治疗或预防。
摘要:
A bioinformatic method for identifying and isolating proteins and peptides with MSCRAMM®-like characteristics from Gram positive bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, and proteins and peptides obtained thereby are provided which can be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.
摘要翻译:提供了用于从革兰氏阳性细菌如肠球菌属,葡萄球菌属,链球菌属和芽孢杆菌属细菌鉴定和分离具有MSCRAMM®样特征的蛋白质和肽的生物信息学方法,以及由此得到的蛋白质和肽,其可用于预防和治疗 革兰氏阳性菌引起的感染。 该方法包括从序列信息中鉴定具有推定的C末端LPXTG(SEQ ID NO:1)细胞壁分选信号的蛋白质和具有LPXTG锚定的细胞壁蛋白质的MSCRAMM®蛋白质的其他结构相似性的蛋白质。 使用本发明鉴定和分离的MSCRAMM蛋白质及其免疫原性区域可用于革兰氏阳性细菌感染的诊断,治疗或预防。
摘要:
A bioinformatic method is provided for identifying and isolating proteins with MSCRAMM®—like characteristics from Gram positive bacteria, such as Enterococcus, Staphylococcus, Streptococcus and Bacillus bacteria, which can then be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM® proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM® proteins and immunogenic regions therein that are identified and isolated using the present invention may be used to generate antibodies useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.
摘要翻译:提供了一种生物信息学方法,用于从革兰氏阳性菌(例如肠球菌属,葡萄球菌属,链球菌属和芽孢杆菌属细菌)中鉴定和分离具有类似MSCRAMM(R)样特征的蛋白质,其可用于预防和治疗由革兰氏阴性菌引起的感染的方法, 阳性细菌。 该方法包括从序列信息中鉴定具有推定的C末端LPXTG(SEQ ID NO:1)细胞壁分选信号的蛋白质和具有LPXTG锚定的细胞壁蛋白质的MSCRAMM蛋白质的其它结构相似性的蛋白质。 使用本发明鉴定和分离的MSCRAMM蛋白质及其免疫原性区域可用于产生用于诊断,治疗或预防革兰氏阳性细菌感染的抗体。
摘要:
Disclosed are the cna gene and cna-derived nucleic acid segments from Staphylococcus aureus, and DNA segments encoding cna from related bacteria. Also disclosed are Col binding protein (CBP) compositions and methods of use. The CBP protein and antigenic epitopes derived therefrom are contemplated for use in the treatment of pathological infections, and in particular, for use in the prevention of bacterial adhesion to Col. DNA segments encoding these proteins and anti-(Col binding protein) antibodies will also be of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of bacterial colonization in an animal such as a human. These DNA segments and the peptides derived therefrom are contemplated for use in the preparation of vaccines and, also, for use as carrier proteins in vaccine formulations, and in the formulation of compositions for use in the prevention of S. aureus infection.